Details of the Drug Combination

General Information of Drug Combination (ID: DCQP1PZ)

Drug Combination Name
BIO-300 Topetecan
Indication
Disease Entry Status REF
Pleural epithelioid mesothelioma Investigative [1]
Component Drugs BIO-300   DMJ7NVI Topetecan   DMAE6LK
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: NCI-H226
Zero Interaction Potency (ZIP) Score: 1.03
Bliss Independence Score: 3.15
Loewe Additivity Score: 6.53
LHighest Single Agent (HSA) Score: 8.24

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of BIO-300
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
Rheumatoid arthritis FA20 Phase 1 [3]
Indication(s) of Topetecan
Disease Entry ICD 11 Status REF
Small-cell lung cancer 2C25.Y Approved [4]
Topetecan Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult acute myeloid leukemia DCYNT8X HL-60(TB) Investigative [6]
Astrocytoma DCPYOCR U251 Investigative [6]
Glioma DCJSQAO SF-295 Investigative [6]
High grade ovarian serous adenocarcinoma DCSUQJG NCI\\/ADR-RES Investigative [1]
Minimally invasive lung adenocarcinoma DCWUKGQ NCI-H322M Investigative [1]
------------------------------------------------------------------------------------

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Clinical pipeline report, company report or official report of Humanetics.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020671.
5 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
6 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.